Adaptive Pathways create win-win scenarios for patients and pharma

Eric NormanAdaptive Licensing, Articles

QuintilesIMS, May 2017
Jon Resnick

In Europe, the concept of ‘adaptive pathways’ offers a faster route to critical medicines for patients with highest unmet needs through an iterative process of early and continuous evidence generation. Despite some criticisms, increased cross-stakeholder interest, including ongoing initiatives led by mIT, may provide a clearer path for this controversial approach. If successful, adaptive pathways could streamline the broader drug development process for the benefit of all parties – especially in rare disease treatments where niche populations and limited data can be a major barrier to access.

Read the article